ORAL IPTACOPAN THERAPY IN C3 GLOMERULOPATHY SHOWS CONSISTENT STABILIZATION OF eGFR SLOPE ACROSS PATIENT SUBGROUPS

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

Presented the abstract " "
(Abstract co-author(s): )

Back

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.

E-Poster Format Requirements

PDF file
Layout: Portrait (vertical orientation)
One page only (Dim A4: 210 x 297mm or PPT)
E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
File Size: Maximum file size is 2 Megabytes (2 MB)
No hyperlinks, animated images, animations, and slide transitions
Language: English
Include your abstract number
E-posters can include QR codes, tables and photos

E-Poster

https://storage.unitedwebnetwork.com/files/1099/5909defdd422724d75708dd21af60c6d.pdf

Abstract Title *

ORAL IPTACOPAN THERAPY IN C3 GLOMERULOPATHY SHOWS CONSISTENT STABILIZATION OF eGFR SLOPE ACROSS PATIENT SUBGROUPS

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

The title will not be accepted if it exceeds 25 words.
Type in CAPITAL LETTERS.
Lowercase may be used for abbreviations only, for example, mRNA.

Co-author 1

David Kavanagh David.Kavanagh@newcastle.ac.uk Royal Victoria Infirmary National Renal Complement Therapeutics Centre Newcastle upon Tyne United Kingdom *

Co-author 2

Andrew S Bomback asb68@cumc.columbia.edu Columbia University Irving Medical Center David Koch Jr. Glomerular Kidney Center New York United States -

Co-author 3

Carla M Nester carla-nester@uiowa.edu University of Iowa Stead Family Children’s Hospital Iowa City United States -

Co-author 4

Richard JH Smith richard-smith@uiowa.edu The University of Iowa Roy J and Lucille A Carver College of Medicine The Molecular Otolaryngology and Renal Research Laboratories Iowa City United States -

Co-author 5

Liz Lightstone l.lightstone@imperial.ac.uk Centre for Inflammatory Disease, Imperial College London Department of Immunology and Inflammation London United Kingdom - Imperial College Renal and Transplant Centre, Hammersmith Hospital Imperial College Healthcare NHS Trust London United Kingdom

Co-author 6

Marina Vivarelli marina.vivarelli@opbg.net Ospedale Pediatrico Bambino Gesù IRCCS Nephrology Division Rome Italy -

Co-author 7

Sophie Chauvet sophie.chauvet@aphp.fr European Hospital Georges Pompidou, APHP Department of Nephrology Paris France - Université Paris Cité FHU COMET Paris France

Co-author 8

Ming-Hui Zhao mhzhao@bjmu.edu.cn Peking University First Hospital Renal Division Beijing China -

Co-author 9

Aiko PJ de Vries a.p.j.de_vries@lumc.nl Leiden University Medical Center Department of Medicine, Division of Nephrology; and Leiden Transplant Center Leiden Netherlands -

Co-author 10

Jean Grisouard jean-1.grisouard@novartis.com Novartis Pharma AG Global Drug Development Basel Switzerland -

Co-author 11

David Lawrence david.lawrence@novartis.com Novartis Pharma AG Global Drug Development Basel Switzerland -

Co-author 12

Anna Aldea anna.aldea@novartis.com Novartis Farmacéutica SA Global Drug Development Barcelona Spain -

Co-author 13

Olivier Somenzi oli.somenzi@novartis.com Novartis Pharma AG Global Drug Development Basel Switzerland -

Co-author 14

Giuseppe Remuzzi giuseppe.remuzzi@marionegri.it Centro Anna Maria Astori IRCCS Istituto di Ricerche Farmacologiche Mario Negri Bergamo, Lombardia Italy -

Co-author 15